Beth Israel Deaconess Medical Center
Epoetin alfa might minimize ribavirin-related blood disorders
Published in Pharma Investments, Ventures and Law Weekly, July 18th, 2004
According to a study from the United States, "the current standard of care for the treatment of hepatitis C virus (HCV) infection is the use of interferon alfa-2a or alfa-2b, standard (IFN) or pegylated (PEG-IFN), in combination with ribavirin (RBV). PEG-IFN is now the most commonly used IFN formulation because of its less frequent dosing requirement and overall improved sustained virologic response (SVR) rates. Patient adherence to these combination treatment regimens, particularly patients who have genotype 1 infection, appears to be important for viral eradication and achievement of an SVR."
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- Advanced Medical Optics, Inc.
Ophthalmic surgical device maker reports preliminary 2005 guidance - BioLineRx
Israeli pharmaceutical firm completes management team - Biophan Technologies, Inc.
Financing option to be discussed at meeting by device firm - Business & Finance
I-trax awarded first health system contract for population health management - Business & Finance
Walgreens purchases Osco patient prescription records - Calypte Biomedical Corporation
Device maker files registration statement for sale of stock - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
